Iovance Biotherapeutics, Inc. Common Stock (IOVA) — Analysis Summary
Iovance Biotherapeutics, Inc. Common Stock (IOVA) has a market cap of $1.83B with year-over-year revenue growth of +60.6%. Net margin stands at -148.4%. The stock trades at a P/E ratio of -5.2.
Key Takeaways
- Revenue changed +60.6% year-over-year
- Net margin of -148.4%
- P/E ratio of -5.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, IOVA posted revenue growth of +60.6% and trades at a P/E of -5.2.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.